Fusion Biopsy Market Size & Share 2025 to 2034

Fusion Biopsy Market Size

The global fusion biopsy market size was valued at USD 829.1 million in 2024 and is expected to exhibit growth at a CAGR of 9.9% from 2025 to 2034. High market growth can be attributed to the increasing prevalence of prostate cancer, growing awareness and screening programs, and supportive government policies and reimbursement, among other contributing factors.

Fusion biopsy is an advanced diagnostic technique that combines MRI and ultrasound imaging to accurately identify and target suspicious tissue areas for biopsy, particularly in organs like the prostate. Prostate cancer ranks among the most prevalent cancers in men, particularly affecting older adults. According to the National Cancer Institute, approximately 248,530 new cases of prostate cancer were diagnosed in the U.S. in 2023. The rising incidence can be attributed to an aging population as well as heightened awareness and screening efforts. Conventional biopsy methods often fall short in precision, leading to missed diagnoses or underestimation of the disease's stage.
 

In contrast, fusion biopsy enhances accuracy by integrating magnetic resonance imaging (MRI) with real-time ultrasound imaging, effectively pinpointing suspicious areas within the prostate. Additionally, as more patients opt for active surveillance for low-risk prostate cancer, there is a growing need for highly accurate diagnostic tools like fusion biopsy. Fusion biopsy enables regular, precise monitoring of prostate changes, helping healthcare providers manage patients on active surveillance more effectively. This capability has made fusion biopsy an essential tool in many urology practices, further driving its demand within the market.
 

Fusion Biopsy Market Trends

Advancements in imaging technology are pivotal growth drivers for the market, significantly enhancing the accuracy, reliability, and accessibility of prostate cancer diagnostics.
 

• Enhanced imaging technologies allow for high-resolution, highly detailed visualization of the prostate, making it easier to identify even small or hard-to-detect tumors. Modern fusion biopsy systems integrate these advancements to accurately locate suspicious lesions and improve diagnostic precision. This increased accuracy reduces the risk of missed tumors, leading to better detection of clinically significant prostate cancer and fewer false negatives. As healthcare providers seek tools that enable early and accurate diagnosis, the improved precision from advanced imaging drives demand for fusion biopsy systems.
   
• Additionally, recent advancements in real-time ultrasound technology and MRI-ultrasound fusion software have improved the guidance and accuracy of biopsy needle placement. By enabling physicians to target only specific, MRI-identified lesions, fusion biopsy minimizes unnecessary sampling of benign areas. This precision results in less discomfort for patients and fewer complications, positioning fusion biopsy as a preferred approach for urologists and radiologists. The technological improvements in real-time imaging directly contribute to the market growth of fusion biopsy systems.
   

Fusion Biopsy Market Analysis

Based on product type, the market is classified into devices and accessories. The devices segment generated the highest revenue of USD 703.1 million in 2024.
 

• With rising awareness of the benefits of fusion biopsy, healthcare facilities have increasingly invested in MRI-ultrasound fusion systems to improve diagnostic accuracy in prostate cancer detection. These systems allow clinicians to overlay MRI images onto real-time ultrasound, enhancing visibility and enabling precise guidance for biopsy procedures. As hospitals and clinics prioritize high-quality diagnostic tools, the demand for fusion biopsy devices has continued to grow, contributing to the segment’s dominant market share.
   
• The devices segment has also benefited from a growing emphasis on early detection and active surveillance programs for prostate cancer. Due to their precision, fusion biopsy devices are frequently used in these programs to monitor patients with suspected or low-risk prostate cancer. The ability to conduct accurate, minimally invasive biopsies with fusion biopsy devices makes them highly suitable for regular monitoring, further increasing their demand in the market.
   

Based on procedure type, the fusion biopsy market is classified into transrectal and transperineal. The transrectal segment accounted for USD 677.6 million in market revenue in 2024 and is anticipated to grow at a CAGR of 9.6% between the 2025 and 2034.
 

• The transrectal approach enables clinicians to accurately reach various areas within the prostate, ensuring that targeted lesions identified in MRI images can be precisely biopsied. This accuracy is essential for detecting clinically significant prostate cancer, leading to more effective diagnosis and treatment planning. As healthcare providers prioritize diagnostic reliability, the transrectal method remains the preferred choice, reinforcing its dominant market share.
   
• Additionally, this approach is a well-established procedure that most urologists and radiologists are trained to perform, making it a practical choice in clinical settings. The familiarity with this approach, combined with a well-defined procedural workflow, enables clinicians to achieve consistent and effective results. This familiarity has contributed to the sustained dominance of the transrectal segment in the market, as hospitals and clinics prefer a standardized, widely accepted method.
   

Based on application, the fusion biopsy market is classified into prostate cancer diagnosis, kidney cancer diagnosis, and other applications. The prostate cancer diagnosis segment generated the highest revenue of USD 549.8 million in 2024.
 

• Fusion biopsy’s ability to pinpoint lesions identified in MRI systems has revolutionized the diagnostic process, significantly reducing false-negative results. This precision is essential for diagnosing clinically significant prostate cancer that might be missed by standard biopsy methods. Healthcare providers recognize the value of accurate targeting in prostate cancer diagnosis, leading to a preference for fusion biopsy as the method of choice and supporting the growth of this segment in the market.
   
• Additionally, awareness campaigns and healthcare initiatives emphasizing the importance of early prostate cancer detection have encouraged men to seek screening and diagnostic tests sooner. Early detection improves treatment outcomes and increases survival rates, making accurate diagnostic tools like fusion biopsy critical. This increased awareness has bolstered demand for fusion biopsy, furthering the market share of the prostate cancer diagnosis segment.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the fusion biopsy market is segmented into hospitals, diagnostic imaging centers, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 1.2 billion by 2034
 

• Hospitals are equipped with advanced MRI and ultrasound fusion systems, making them well-suited for fusion biopsy procedures. These facilities typically have the infrastructure and technical capabilities to integrate high-resolution imaging technologies required for accurate biopsy targeting. The availability of state-of-the-art equipment in hospitals attracts patients and clinicians seeking precise diagnostic tools, bolstering the hospitals segment’s dominant market share in the market.
   
• Hospitals often employ specialized staff, including radiologists, urologists, and technologists, who are trained to perform complex fusion biopsy procedures. The expertise and experience offered by hospital professionals enhance the accuracy and reliability of fusion biopsy, making hospitals a preferred setting for these procedures. This concentration of skilled personnel supports the high adoption rate of fusion biopsy in hospitals, reinforcing their leading market position.

North America fusion biopsy market accounted for USD 367.1 million in market revenue in 2024 and is anticipated to grow at a CAGR of 9.2% between the 2025 and 2034.
 

• North America holds a dominant market share in the market, driven by the region’s advanced healthcare infrastructure, high incidence of prostate cancer, and widespread adoption of cutting-edge diagnostic technologies.
   
• In the U.S., prostate cancer is one of the most commonly diagnosed cancers among men, creating strong demand for reliable diagnostic tools like fusion biopsy. Healthcare providers across North America, supported by favorable reimbursement policies and substantial healthcare spending, have increasingly integrated MRI-ultrasound fusion biopsy as a standard approach in prostate cancer diagnostics.
   

France fusion biopsy market is projected to grow remarkably in the coming years.
 

• France has placed a strong emphasis on early detection and accurate diagnosis of prostate cancer, supported by public awareness initiatives and national health policies. The country’s high-quality healthcare facilities and trained professionals enable hospitals and diagnostic centers to offer precision diagnostic services, including fusion biopsy.
   
• Moreover, French healthcare providers benefit from government support for cancer research and diagnosis, accelerating the uptake of fusion biopsy technology across the country, contributing to its notable market share in Europe.
   

Japan holds a dominant position in the Asia Pacific fusion biopsy market.
 

• Japanese healthcare providers have increasingly adopted fusion biopsy to improve diagnostic accuracy in prostate cancer cases, aiming to detect and treat cases in earlier stages. Japan’s healthcare system, known for its technological sophistication and high standard of care, has quickly embraced MRI-ultrasound fusion systems to offer patients precise diagnostic options.
   
• Additionally, the Japanese government’s support for healthcare advancements and early diagnosis initiatives has bolstered the adoption of fusion biopsy in hospitals and clinics, securing Japan's significant market share in the market in Asia Pacific.
   

Fusion Biopsy Market Share

The market is competitive, with a mix of large multinationals like Koninklijke Philips N.V., Focal Healthcare, and Koelis leading in innovation and extensive product portfolios. Regional companies and new entrants, particularly from APAC, are also making significant strides. The market is characterized by frequent technological advancements, such as improved precision, enhanced real-time guidance, and increased workflow efficiency, which drive ongoing product development. Strategic partnerships, mergers, and acquisitions are common as companies seek to expand market reach and enhance their technological capabilities.
 

Fusion Biopsy Market Companies

Prominent players operating in the fusion biopsy industry include:

• Canon Medical Systems
• CIVCO Medical Solutions
• Eigen Health
• Esaote SpA
• Exact imaging
• Focal Healthcare
• GE HealthCare
• Koelis
• Koninklijke Philips N.V.
• MedCom
• Merit Medical Systems
• Siemens Healthineers
   

Fusion Biopsy Industry News:

• In October 2024, GE Healthcare announced that it launched the Versana Premier, an ultrasound system. Versana Premier offers automation and AI-enabled productivity tools to improve workflow. It also has clinical features designed to enhance clinical efficiency and accuracy. This product launch will aid the company  enhance its customer base.
   

The fusion biopsy market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Devices
• Accessories

Market, By Procedure Type

• Transrectal
• Transperineal

Market, By Application

• Prostate cancer diagnosis
• Kidney cancer diagnosis
• Other applications

Market, By End Use

• Hospitals
• Diagnostic imaging centers
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE